Compare Torrent Pharma with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs SUN PHARMA - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA SUN PHARMA TORRENT PHARMA/
SUN PHARMA
 
P/E (TTM) x 59.6 28.5 209.3% View Chart
P/BV x 6.3 2.5 256.4% View Chart
Dividend Yield % 0.8 0.6 125.1%  

Financials

 TORRENT PHARMA   SUN PHARMA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
SUN PHARMA
Mar-19
TORRENT PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,550679 228.3%   
Low Rs1,144375 304.6%   
Sales per share (Unadj.) Rs354.7121.1 292.8%  
Earnings per share (Unadj.) Rs40.113.4 299.6%  
Cash flow per share (Unadj.) Rs64.220.7 310.5%  
Dividends per share (Unadj.) Rs14.002.75 509.1%  
Dividend yield (eoy) %1.00.5 199.3%  
Book value per share (Unadj.) Rs273.1172.6 158.3%  
Shares outstanding (eoy) m169.222,399.26 7.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.84.4 87.3%   
Avg P/E ratio x33.639.4 85.3%  
P/CF ratio (eoy) x21.025.5 82.3%  
Price / Book Value ratio x4.93.1 161.4%  
Dividend payout %34.920.6 169.9%   
Avg Mkt Cap Rs m227,8971,264,650 18.0%   
No. of employees `00014.717.5 84.0%   
Total wages/salary Rs m11,35359,671 19.0%   
Avg. sales/employee Rs Th4,083.016,608.1 24.6%   
Avg. wages/employee Rs Th772.33,409.6 22.7%   
Avg. net profit/employee Rs Th461.31,833.8 25.2%   
INCOME DATA
Net Sales Rs m60,021290,659 20.6%  
Other income Rs m2,98810,255 29.1%   
Total revenues Rs m63,009300,914 20.9%   
Gross profit Rs m13,49363,076 21.4%  
Depreciation Rs m4,08617,533 23.3%   
Interest Rs m3,0855,553 55.6%   
Profit before tax Rs m9,31050,246 18.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-12,144 0.0%   
Tax Rs m2,5296,009 42.1%   
Profit after tax Rs m6,78132,093 21.1%  
Gross profit margin %22.521.7 103.6%  
Effective tax rate %27.212.0 227.1%   
Net profit margin %11.311.0 102.3%  
BALANCE SHEET DATA
Current assets Rs m52,623310,692 16.9%   
Current liabilities Rs m52,022173,396 30.0%   
Net working cap to sales %1.047.2 2.1%  
Current ratio x1.01.8 56.5%  
Inventory Days Days12099 120.7%  
Debtors Days Days76112 68.3%  
Net fixed assets Rs m85,016232,477 36.6%   
Share capital Rs m8462,399 35.3%   
"Free" reserves Rs m45,376411,691 11.0%   
Net worth Rs m46,222414,091 11.2%   
Long term debt Rs m41,11515,226 270.0%   
Total assets Rs m142,432646,938 22.0%  
Interest coverage x4.010.0 40.0%   
Debt to equity ratio x0.90 2,419.1%  
Sales to assets ratio x0.40.4 93.8%   
Return on assets %6.95.8 119.0%  
Return on equity %14.77.8 189.3%  
Return on capital %14.210.2 139.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,58066,025 22.1%   
Fx outflow Rs m3,60038,610 9.3%   
Net fx Rs m10,98027,415 40.1%   
CASH FLOW
From Operations Rs m8,94221,965 40.7%  
From Investments Rs m-47,070-6,813 690.9%  
From Financial Activity Rs m34,174-27,305 -125.2%  
Net Cashflow Rs m-3,655-8,442 43.3%  

Share Holding

Indian Promoters % 71.5 63.7 112.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 5.1 136.8%  
FIIs % 12.6 23.0 54.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 8.3 106.0%  
Shareholders   26,511 133,026 19.9%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

The Week That Was: Of Macro Events and Auto Sector Blues(Podcast)

In yet again holiday shortened week, stock market sentiments were swayed by the macro events such as release of index of industrial production and consumer price index data.

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Sep 13, 2019 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS